Octreotide
1
Reactions 442 - 13 Mar 1993 Octreotide GI disorders: clinical study US researchers found that although patients with active acromegaly commonly experienced adverse GI symptoms during high-dose octreotide therapy, these were usually mild and and transient. Five men and 3 women, aged 23-60 years, self-administered SC octreotide 150microg tid for 9 weeks, increasing to 250microg tid for 2 weeks followed by 500microg tid for 6 weeks. All patients observed GI side effects including abdominal gas (n = 7), transient nausea postinjection (3), soft stools (3) and increased frequency of bowel movements (1). One patient required a reduction in octreotide dosage to 450microg. All symptoms resolved after the drug was discontinued. Mean faecal fat excretion after high-dose octreotide was significantly higher than the baseline level (11 vs 6.6 g/24h), but after a 5-week washout period, this value decreased to the pretreatment value. Mean fasting serum carotene levels, plasma xylose levels and urinary xylose levels were unchanged by octreotide therapy. After carotene loading, serum carotene levels did not correlate with fat malabsorption. No new cholelithiasis was observed in any patient Ho PJ, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Digestive Diseases and Sciences 38: 309-315, Feb 1993 - USA 800183504 1 Reactions 13 Mar 1993 No. 442 0114-9954/10/0442-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Octreotide
Reactions 442 - 13 Mar 1993
Octreotide
GI disorders: clinical studyUS researchers found that although patients with active
acromegaly commonly experienced adverse GI symptomsduring high-dose octreotide therapy, these were usually mildand and transient. Five men and 3 women, aged 23-60 years,self-administered SC octreotide 150microg tid for 9 weeks,increasing to 250microg tid for 2 weeks followed by500microg tid for 6 weeks. All patients observed GI side effectsincluding abdominal gas (n = 7), transient nauseapostinjection (3), soft stools (3) and increased frequency ofbowel movements (1). One patient required a reduction inoctreotide dosage to 450microg. All symptoms resolved afterthe drug was discontinued. Mean faecal fat excretion afterhigh-dose octreotide was significantly higher than the baselinelevel (11 vs 6.6 g/24h), but after a 5-week washout period, thisvalue decreased to the pretreatment value. Mean fastingserum carotene levels, plasma xylose levels and urinary xyloselevels were unchanged by octreotide therapy. After caroteneloading, serum carotene levels did not correlate with fatmalabsorption. No new cholelithiasis was observed in anypatientHo PJ, et al. Effect of chronic octreotide treatment on intestinal absorption inpatients with acromegaly. Digestive Diseases and Sciences 38: 309-315, Feb 1993- USA 800183504
1
Reactions 13 Mar 1993 No. 4420114-9954/10/0442-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
![BS 499 Part 1 [1965]](https://static.fdocuments.nl/doc/165x107/54081862dab5cac8598b460a/bs-499-part-1-1965.jpg)
